Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Chief Innovation Officer | March 12, 2026 | March 16, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Scientific Officer | January 20, 2022 | January 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 421,446 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Purchase · Acquired 100,000 · Balance 421,446 F1: Open market purchase of shares in accordance with Issuer's trading policies. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase of shares in accordance with Issuer's trading policies.
Korsana Biosciences, Inc.
Report date January 20, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-01-20 | Direct | 135,000 |
Reported balance
After 2022-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-20 · Grant · Acquired 135,000 · Balance 135,000 F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 16, 2026 20:17 UTC | Absci Corp ABSI · Entity 4685 | PurchaseCommon Stock | 100,000 | $2.29 | $229,000.00 |
DisclosureSEC source: 0001672688-26-000049 · wk-form4_1773692239.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,446 F1 · shares: Open market purchase of shares in accordance with Issuer's trading policies. F1 · acquired: Open market purchase of shares in accordance with Issuer's trading policies. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 02:03 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 1,257 | $2.80 | $3,519.60 |
DisclosureSEC source: 0001672688-26-000035 · wk-form4_1772676221.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,446 F1 · shares: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:53 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 1,469 | $2.99 | $4,392.31 |
DisclosureSEC source: 0001672688-26-000018 · wk-form4_1770241991.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,703 F1 · shares: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 14, 2025 Filed Oct 14, 2025 20:50 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 3,092 | $3.68 | $11,378.56 |
DisclosureSEC source: 0001672688-25-000067 · wk-form4_1760474998.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,172 F1 · shares: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 12:37 UTC | Absci Corp ABSI · Entity 4685 | PurchaseCommon Stock | 50,000 | $3.04 | $152,000.00 |
DisclosureSEC source: 0001628280-25-036325 · wk-form4_1753792661.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,264 F1 · kind: Open market purchase of shares in accordance with Issuer's trading policies. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:40 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 93,700 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001672688-25-000016 · wk-form4_1741128009.xml · derivative · entry 2 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,700 Underlying: Common Stock · 93,700 shares Expires 2035-03-02 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on March 3, 2026, subject to the Reporting Person's continuous service to the Issuer on such date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:40 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 23,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-25-000016 · wk-form4_1741128009.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,264 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 3, 2026, subject to the Reporting Person's continuous service to the Issuer on such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:30 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 1,469 | $3.71 | $5,449.99 |
DisclosureSEC source: 0001672688-25-000006 · wk-form4_1738704621.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,564 F1 · shares: Represents the number of shares of Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| October 12, 2024 Filed Oct 16, 2024 21:59 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 3,092 | $4.07 | $12,584.44 |
DisclosureSEC source: 0001672688-24-000043 · wk-form4_1729115984.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,033 F1 · shares: Represents the number of shares of Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:14 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 349,625 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001672688-24-000013 · wk-form4_1707178418.xml · derivative · entry 2 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,625 Underlying: Common Stock · 349,625 shares Expires 2034-01-31 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on February 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:14 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 83,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-24-000013 · wk-form4_1707178418.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,125 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on February 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 12, 2023 Filed Oct 16, 2023 22:11 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-23-000034 · wk-form4_1697494297.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled as to 1/3rd of RSUs on October 12, 2024, and thereafter, the remaining RSUs will vest on an annual basis in two (2) equal installments, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:41 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001672688-23-000010 · wf-form4_167788326062307.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of the shares subject to this option, vest and become exercisable on March 1, 2024, and the remaining 75% of the shares subject to this option, vest and become exercisable in 36 equal monthly installments thereafter, until March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 00:31 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 2,000,009 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001628280-22-026065 · wf-form4_166501625432266.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,009 Underlying: Common Stock · 2,000,009 shares Expires 2032-10-02 F1 · derivative.exercise_date: 25% of the shares subject to this option vest and become exercisable on September 30, 2023, and thereafter, the remaining shares subject to this option vest and become exercisable in 36 approximately equal monthly installments until September 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:52 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 4,783 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001628280-22-016855 · wf-form4_165489433123279.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,783 Underlying: Common Stock · 4,783 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 22:00 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 45,180 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001628280-22-006819 · wf-form4_164790000030881.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,180 Underlying: Common Stock · 45,180 shares Expires 2032-03-16 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 36 approximately equal monthly installments beginning on March 17, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:48 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001140361-22-002458 · form4.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:32 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-21-041210 · form4.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 125,000 | $2.53 | $316,250.00 |
DisclosureSEC source: 0001209191-20-058031 · doc4.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,704 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.60, inclusive. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range. F2 · balance_after: The reporting person acquired 2,204 and 2,500 shares of Common Stock under the issuer's employee stock purchase plan on November 29, 2019 and May 29, 2020, respectively. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-20-057302 · doc4.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-11-04 F1 · derivative.exercise_date: The Option vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of November 4, 2020. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 22:41 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-058158 · doc4.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. F2 · derivative.expiration_date: To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:02 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 125,000 | $1.82 | $227,500.00 |
DisclosureSEC source: 0001209191-19-057112 · doc4.xml · nonDerivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:18 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $15.40 | $0.00 |
DisclosureSEC source: 0001209191-19-026820 · doc4.xml · derivative · entry 1 Busch Andreas · CIK 0001775029 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: The option, granted as a new hire award, vests as to 25% of the shares of Common Stock on the first anniversary of April 29, 2019 and 1/48th of the shares of Common Stock vest each month thereafter for the next 36 months, based on his continued employment by a subsidiary of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.